COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

  1. Turner, Paul J.
  2. Ansotegui, Ignacio J.
  3. Campbell, Dianne E.
  4. Cardona, Victoria
  5. Ebisawa, Motohiro
  6. El-Gamal, Yehia
  7. Fineman, Stanley
  8. Geller, Mario
  9. Gonzalez-Estrada, Alexei
  10. Greenberger, Paul A.
  11. Leung, Agnes S.Y.
  12. Levin, Michael E.
  13. Muraro, Antonella
  14. Sánchez Borges, Mario
  15. Senna, Gianenrico
  16. Tanno, Luciana K.
  17. Thong, Bernard Yu-Hor
  18. Worm, Margitta

Download
1-s2.0-S1939455121000119-main.pdf 1015,63KB
WeightNameValue
1000 Titel
  • COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
1000 Autor/in
  1. Turner, Paul J. |
  2. Ansotegui, Ignacio J. |
  3. Campbell, Dianne E. |
  4. Cardona, Victoria |
  5. Ebisawa, Motohiro |
  6. El-Gamal, Yehia |
  7. Fineman, Stanley |
  8. Geller, Mario |
  9. Gonzalez-Estrada, Alexei |
  10. Greenberger, Paul A. |
  11. Leung, Agnes S.Y. |
  12. Levin, Michael E. |
  13. Muraro, Antonella |
  14. Sánchez Borges, Mario |
  15. Senna, Gianenrico |
  16. Tanno, Luciana K. |
  17. Thong, Bernard Yu-Hor |
  18. Worm, Margitta |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-03
1000 Erschienen in
1000 Quellenangabe
  • 14(2):100517
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.waojou.2021.100517 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857113 |
1000 Ergänzendes Material
  • https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00011-9/fulltext#supplementaryMaterial |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine.In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Anaphylaxis
lokal Polyethylene glycol
lokal Vaccine
lokal Adverse event following immunization
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VHVybmVyLCBQYXVsIEou|https://frl.publisso.de/adhoc/uri/QW5zb3RlZ3VpLCBJZ25hY2lvIEou|https://frl.publisso.de/adhoc/uri/Q2FtcGJlbGwsIERpYW5uZSBFLg==|https://frl.publisso.de/adhoc/uri/Q2FyZG9uYSwgVmljdG9yaWE=|https://frl.publisso.de/adhoc/uri/RWJpc2F3YSwgTW90b2hpcm8=|https://frl.publisso.de/adhoc/uri/RWwtR2FtYWwsIFllaGlh|https://frl.publisso.de/adhoc/uri/RmluZW1hbiwgU3RhbmxleQ==|https://frl.publisso.de/adhoc/uri/R2VsbGVyLCBNYXJpbw==|https://frl.publisso.de/adhoc/uri/R29uemFsZXotRXN0cmFkYSwgQWxleGVp|https://frl.publisso.de/adhoc/uri/R3JlZW5iZXJnZXIsIFBhdWwgQS4=|https://frl.publisso.de/adhoc/uri/TGV1bmcsIEFnbmVzIFMuWS4=|https://frl.publisso.de/adhoc/uri/TGV2aW4sIE1pY2hhZWwgRS4=|https://frl.publisso.de/adhoc/uri/TXVyYXJvLCBBbnRvbmVsbGE=|https://frl.publisso.de/adhoc/uri/U8OhbmNoZXogQm9yZ2VzLCBNYXJpbw==|https://frl.publisso.de/adhoc/uri/U2VubmEsIEdpYW5lbnJpY28=|https://frl.publisso.de/adhoc/uri/VGFubm8sIEx1Y2lhbmEgSy4=|https://frl.publisso.de/adhoc/uri/VGhvbmcsIEJlcm5hcmQgWXUtSG9y|https://frl.publisso.de/adhoc/uri/V29ybSwgTWFyZ2l0dGE=
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427813.rdf
1000 Erstellt am 2021-06-01T08:52:17.609+0200
1000 Erstellt von 284
1000 beschreibt frl:6427813
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2021-10-01T08:12:48.561+0200
1000 Objekt bearb. Fri Oct 01 08:12:33 CEST 2021
1000 Vgl. frl:6427813
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427813 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source